Saxton R E, Mann B D, Morton D L, Burk M W
Hybridoma. 1982;1(4):433-45. doi: 10.1089/hyb.1.1982.1.433.
Two monoclonal antibodies produced by hybridomas were identified by an indirect 125I-protein A binding assay that define cell surface antigens expressed on cultured human melanoma cells but not on autologous lymphoblastoid cells. The first antibody, 705F6 (an IgG2b immunoglobulin), bound to 14/14 melanoma lines, 6/9 carcinomas and sarcomas, 7/7 gliomas and neuroblastomas, 2/2 fetal cell lines, 0/8 lymphoblastoid cell lines, and weakly to 2/4 leukemia lines. The second monoclonal antibody, 436G10 (IgG1), reacted with 10/14 melanomas 5/13 carcinomas and sarcomas, 2/7 gliomas and neuroblastomas, and weakly with the fetal cells, but not with the leukemic or lymphoblastoid cell lines. Comparison of 705F6 and 436G10 with 28 other monoclonal antibodies from different laboratories identified several with similar binding patterns to a panel of tumor and nontumor cell lines. Crossblocking of 125I-labeled 436G10 was not observed by R23, I12 or L10 antibodies. However, 705F6 was completely blocked by monoclonal 376.96S, showing that these two antibodies bind to the same antigenic determinant. The 705F6 antibody immunoprecipitated a 95 kd (kilodalton) membrane protein and the 436G10 antibody bound a 125 kd protein from 125I-labeled melanoma cells. The broad distribution of these two proteins on melanomas and other solid tumors suggests that they define common oncodevelopmental antigens expressed on proliferating cells.
通过间接125I-蛋白A结合试验鉴定出两种由杂交瘤产生的单克隆抗体,它们可识别在培养的人黑色素瘤细胞上表达但在自体淋巴母细胞系上不表达的细胞表面抗原。第一种抗体705F6(一种IgG2b免疫球蛋白)与14/14黑色素瘤细胞系、6/9癌和肉瘤细胞系、7/7胶质瘤和神经母细胞瘤细胞系、2/2胎儿细胞系结合,与0/8淋巴母细胞系结合较弱,与2/4白血病细胞系结合较弱。第二种单克隆抗体436G10(IgG1)与10/14黑色素瘤、5/13癌和肉瘤、2/7胶质瘤和神经母细胞瘤反应,与胎儿细胞反应较弱,但与白血病或淋巴母细胞系无反应。将705F6和436G10与来自不同实验室的其他28种单克隆抗体进行比较,发现有几种与一组肿瘤和非肿瘤细胞系具有相似的结合模式。R23、I12或L10抗体未观察到对125I标记的436G10的交叉阻断。然而,705F6被单克隆抗体376.96S完全阻断,表明这两种抗体结合相同的抗原决定簇。705F6抗体免疫沉淀出一种95千道尔顿(kd)的膜蛋白,436G10抗体从125I标记的黑色素瘤细胞中结合一种125 kd的蛋白。这两种蛋白在黑色素瘤和其他实体瘤上的广泛分布表明,它们定义了在增殖细胞上表达的常见肿瘤发生相关抗原。